A Phase II Study of the Efficacy and Tolerability of Bicalutamide Plus Aromatase Inhibitors in Estrogen Receptor(+)/Androgen Receptor(+)/HER2(-) Metastatic Breast Cancer
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Bicalutamide (Primary) ; Anastrozole; Exemestane; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms BETTER
- 21 Dec 2017 Planned End Date changed from 1 Jan 2018 to 1 Dec 2018.
- 21 Dec 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 29 Sep 2016 New trial record